News for 'Sun Pharmaceutical Industries'

Open offers highest since 2008 as acquisition, takeover attempts surge

Open offers highest since 2008 as acquisition, takeover attempts surge

Rediff.com29 Dec 2025

Open offers this calendar year, following attempts at acquisition and takeover, came in at more than two a week. There were 121 such open offers to acquire additional shares following a substantial acquisition or change of control, shows the data compiled by primedatabase.com.

Cancer Therapies Break New Ground

Cancer Therapies Break New Ground

Rediff.com26 Dec 2025

'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'

World's 9 Fastest-Growing Cities

World's 9 Fastest-Growing Cities

Rediff.com26 Dec 2025

Asia takes the lead, boasting four Indian cities on the list, according to the 2024 Savills Growth Hubs Index.

India, New Zealand conclude FTA negotiations

India, New Zealand conclude FTA negotiations

Rediff.com22 Dec 2025

New Zealand Prime Minister Christopher Luxon on Monday said the negotiations for a free trade agreement with India have been concluded.

'Is PG Necessary After MBBS?'

'Is PG Necessary After MBBS?'

Rediff.com26 Nov 2025

While having an MBBS degree allows you to offer consultations, having a PG provides you with more credibility and knowledge, explains rediffGURU Dr Nagarajan JSK.

Sensex down 275 points on fag-end selling

Sensex down 275 points on fag-end selling

Rediff.com10 Dec 2025

Among the Sensex constituents, Eternal, Trent, Bharti Airtel, Infosys, Tech Mahindra, UltraTech Cement, ICICI Bank, HDFC Bank, Bajaj Finance, Tata Consultancy Services, Bharat Electronics Ltd, Larsen & Toubro and Tata Motors Passenger Vehicles were the laggards. However, Tata Steel, Sun Pharmaceuticals, ITC, NTPC, Reliance Industries, HCL Technologies, PowerGrid, and Asian Paints were among the gainers.

Sensex jumps 427 points on buying in metal, auto shares

Sensex jumps 427 points on buying in metal, auto shares

Rediff.com11 Dec 2025

Among the Sensex constituents, Eternal, Tata Steel, Kotak Mahindra Bank, UltraTech Cement, Maruti Suzuki India, Sun Pharmaceuticals, Tech Mahindra, HDFC Bank, Tata Motors Passenger Vehicles, Infosys, Trent, Mahindra & Mahindra, Reliance Industries and HCL Technologies were the gainers. However, Asian Paints, Bharti Airtel, Bajaj Finance, PowerGrid, Axis Bank, ICICI Bank and Titan were among the laggards.

India, Oman to ink free trade agreement during PM Narendra Modi visit

India, Oman to ink free trade agreement during PM Narendra Modi visit

Rediff.com13 Dec 2025

Next week's three-nation foreign tour of Prime Minister Narendra Modi will see India and Oman sign a free trade deal. The visit will also pave the way for agreements with Ethiopia and Jordan to increase India's bilateral trade and investments.

What Putin hopes to achieve on his India visit

What Putin hopes to achieve on his India visit

Rediff.com3 Dec 2025

Russian President Vladimir Putin's visit to India this week aims to secure energy supplies, stabilise defence deliveries and ensure bilateral trade continues smoothly despite strong Western sanctions, GTRI said on Tuesday.

Rupee Fall: Who Stands To Gain?

Rupee Fall: Who Stands To Gain?

Rediff.com25 Nov 2025

So far this year, the rupee has fallen by 4.2 per cent, the worst among its Asian peers.

Trump announces 100% tariffs on foreign-made movies, India to be hit

Trump announces 100% tariffs on foreign-made movies, India to be hit

Rediff.com29 Sep 2025

President Trump announces 100% tariffs on movies made outside the US, potentially impacting the Indian film industry. The move follows similar tariffs on pharmaceutical products.

What Weapons Will Putin Sell India On Rare State Visit?

What Weapons Will Putin Sell India On Rare State Visit?

Rediff.com29 Nov 2025

On the table are additional batches of S-400 surface-to-air missile systems from Russia, which India used with immense success during Operation Sindoor. India could buy at least two squadrons of Su-57 fighter jets plus joint production of S-500 air defence systems.

Sensex, Nifty settle with modest gains

Sensex, Nifty settle with modest gains

Rediff.com14 Nov 2025

From the Sensex pack, Eternal, Bharat Electronics Ltd, Trent, Axis Bank, State Bank of India, Bajaj Finance, Sun Pharmaceuticals, Asian Paints, Adani Ports, Hindustan Unilever, Reliance Industries, ITC, PowerGrid, Tata Motors Ltd's Commercial Vehicles business, and Bajaj Finserv were the gainers. Infosys, Tata Motors Passenger Vehicles, Tata Steel, ICICI Bank, Tech Mahindra, Titan, UltraTech Cement, Maruti Suzuki India, and Larsen & Toubro were the laggards.

'Indian Youth Can Expect Career Growth In Russia'

'Indian Youth Can Expect Career Growth In Russia'

Rediff.com4 Dec 2025

'Don't look at Russia only as a place to earn quickly and then leave.' 'Try to build experience in serious companies, skills and certifications that will serve you anywhere in the world.'

Shortcuts Won't Build Industrial Capability

Shortcuts Won't Build Industrial Capability

Rediff.com28 Jul 2025

Any industrial policy is only as good as how it is applied and the other reforms that support it. This was as true 40 years ago as it is now, points out Debashis Basu.

Kremlin Didn't Know About Modi Gesture

Kremlin Didn't Know About Modi Gesture

Rediff.com5 Dec 2025

The Russians have termed Putin's visit to India, his first to this country since the outbreak of the Russia-Ukraine war, as 'Druzhba Dosti', which means 'friendship' in Russian and Hindi respectively.

Sensex jumps 595 points on strong global cues

Sensex jumps 595 points on strong global cues

Rediff.com12 Nov 2025

From the Sensex pack, Asian Paints, Tech Mahindra, Tata Consultancy Services, Bajaj Finserv, Adani Ports, HCL Technologies, Bharti Airtel, Infosys, Trent, Reliance Industries, UltraTech Cement, Sun Pharmaceuticals, Eternal, Titan and Bajaj Finance were the gainers. On the other hand, Tata Steel, Tata Motors Passenger Vehicles, Tata Motors Commercial Vehicles, Bharat Electronics, Kotak Mahindra Bank and PowerGrid were the laggards.

Pharma stocks slide as US headwinds hurt

Pharma stocks slide as US headwinds hurt

Rediff.com16 Sep 2025

Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.

USFDA's new draft biosimilar rules to benefit Indian biotech cos

USFDA's new draft biosimilar rules to benefit Indian biotech cos

Rediff.com9 Nov 2025

The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.

Trump announces 100% tariffs on foreign-made movies, India to be hit

Trump announces 100% tariffs on foreign-made movies, India to be hit

Rediff.com30 Sep 2025

Trump said California has been particularly "hard hit" because of this, blaming democrat Gavin Newsom, the Governor of California, for this loss, calling him "weak and incompetent."

Modi, Putin unveil 2030 roadmap amid US pressure

Modi, Putin unveil 2030 roadmap amid US pressure

Rediff.com5 Dec 2025

India and Russia have solidified a five-year plan to enhance their economic and trade partnership, while also addressing the ongoing conflict in Ukraine and the threat of terrorism.

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Rediff.com26 Sep 2025

Most pharma shares dropped, dragging the BSE Healthcare index down by 2.14 per cent after Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1. Wockhardt shares tanked 9.4 per cent.

Will Tata Sons Get RBI Relief?

Will Tata Sons Get RBI Relief?

Rediff.com24 Oct 2025

Tata Sons, now debt-free, has asked the RBI to drop its 'upper-layer NBFC' tag and allow it to stay private.

Budget 2024: Wishlist of the pharma industry

Budget 2024: Wishlist of the pharma industry

Rediff.com8 Jul 2024

There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.

Where The Deadly Cough Syrup Was Made

Where The Deadly Cough Syrup Was Made

Rediff.com18 Oct 2025

Sandwiched between a Hero MotoCorp showroom and a shop that hires out cooking utensils is a small, dingy building that's been locked up. The non-descript two-room building is a manufacturing unit of Sresan Pharmaceuticals, the pharma company made its Coldriff cough syrup that has allegedly killed 25 children in Madhya Pradesh.

Tylenol row may not hit India's pharma exports

Tylenol row may not hit India's pharma exports

Rediff.com29 Sep 2025

Amid controversy over USPresident Donald Trump's comments linking the use of Tylenol and other related paracetamol products by pregnant women to autism in children, experts and industry executives say that since India's export of the drug to the US is less, it will hardly affect the country's pharma exports to America.

Cough syrup deaths: No state follows pharma safety norms

Cough syrup deaths: No state follows pharma safety norms

Rediff.com10 Oct 2025

The Central Drugs Standard Control Organisation (CDSCO) will conduct testing, inspection and auditing of cough syrup manufacturers.

Want To Invest In Manufacturing Funds?

Want To Invest In Manufacturing Funds?

Rediff.com3 Nov 2025

'They are a poor fit for anyone with near-term goals, low volatility tolerance, or a need for steady income or liquidity.' 'First-time investors should typically avoid them.'

Mankind taps OpenAI to institutionalise AI in ops

Mankind taps OpenAI to institutionalise AI in ops

Rediff.com18 Sep 2025

Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.

Cough syrup deaths: IMA slams doctor's arrest

Cough syrup deaths: IMA slams doctor's arrest

Rediff.com7 Oct 2025

The Indian Medical Association (IMA) has defended a doctor arrested in connection with cough syrup deaths in Madhya Pradesh, attributing the incident to failures in the drugs regulatory system.

GST cut on drugs, medical devices to help patients

GST cut on drugs, medical devices to help patients

Rediff.com4 Sep 2025

The government's move to cut GST on medicines and medical devices while exempting lifesaving drugs from the levy is a bold step that will bring direct relief to patients and families while significantly reducing financial strain on them, pharmaceuticals and healthcare industry players said on Thursday.

How India's pharma cos plan to tackle steep US tariffs

How India's pharma cos plan to tackle steep US tariffs

Rediff.com10 Sep 2025

As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.

Cough syrup deaths: Many states ban Coldrif; MP suspends officials

Cough syrup deaths: Many states ban Coldrif; MP suspends officials

Rediff.com7 Oct 2025

A special investigation team (SIT) has been formed in Madhya Pradesh to investigate the deaths of 14 children in Chhindwara, suspected to be linked to a toxic cough syrup. The investigation includes arrests, exhumations, and a ban on the implicated cough syrup.

Trump's drug price cut plan may put pressure on India

Trump's drug price cut plan may put pressure on India

Rediff.com12 May 2025

US President Donald Trump's plan to sign an executive order to cut prescription drug prices by 30-80 per cent could lead to a global price adjustment with pharma firms pushing lower-cost countries like India to raise prices, according to the economic think tank GTRI. The US move could push prices in lower-cost countries like India as manufacturers would seek to recover losses and R&D costs from these nations.

From 1905 cry to Modi's 'Vocal for Local': NCERT's new Swadeshi lessons

From 1905 cry to Modi's 'Vocal for Local': NCERT's new Swadeshi lessons

Rediff.com3 Oct 2025

Two modules published by the NCERT, Swadeshi: Vocal for Local (for middle stage) and Swadeshi: For a Self-Reliant India (for secondary stage), carry excerpts from the prime minister's Independence Day address in which he stressed that self-reliance would drive India's journey towards a Viksit Bharat.

Factors that will drive the markets this week

Factors that will drive the markets this week

Rediff.com28 Sep 2025

Stock markets will be driven by RBI's interest rate decision, tariff-related developments, global trends and trading activity of foreign investors in this holiday-shortened week, analysts said.

Govt Targets 100 Products For Aatmanirbhar Push

Govt Targets 100 Products For Aatmanirbhar Push

Rediff.com16 Sep 2025

'Our endeavour will be that we identify these products, put them in the public domain so that the manufacturers can look at them and give a boost to Make in India.'

Credit quality of companies likely to remain stable in H2

Credit quality of companies likely to remain stable in H2

Rediff.com8 Oct 2025

Credit quality of Indian corporate is expected to be stable in the second half of the current financial year (H2FY26), supported by easing monetary cycle, and declining inflation, coupled with income-tax relief and rationalisation of the goods and service tax (GST) rates, among others.

India relationship...: What Rubio said after Jaishankar meet

India relationship...: What Rubio said after Jaishankar meet

Rediff.com23 Sep 2025

Rubio voiced "appreciation" for New Delhi's continued engagement on bilateral issues, including trade, defence and energy.

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Rediff.com30 Jun 2025

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.